⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12597147 | 0.83 | RAB9A (0.54) | — | |
| SCHEMBL424283 | 0.81 | — | — | |
| SCHEMBL12763782 | 0.79 | RAB9A (0.54) | — | |
| SCHEMBL4099165 | 0.79 | RAB9A (0.59) | — | |
| SCHEMBL26894497 | 0.78 | — | — | |
| SCHEMBL15286383 | 0.78 | RAB9A (0.53) | — | |
| SCHEMBL12126320 | 0.78 | RAB9A (0.53) | — | |
| SCHEMBL24590345 | 0.77 | RAB9A (0.57) | — | |
| SCHEMBL18398869 | 0.77 | — | — | |
| SCHEMBL2170914 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9610317-B2 | 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20160082069-A1 | 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS, INC. | 2016-03-24 | — | — | US | disclosed |
| US-9233136-B2 | 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-01-12 | — | — | US | disclosed |
| WO-2015140133-A1 | PIPERIDINE-DIONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-09-24 | — | — | WO | disclosed |
| WO-2015142903-A2 | METHOD OF CONTROLLING LACTATE PRODUCTION WITH PIPERDINE-DIONE DERIVATIVES | GENENTECH, INC. (US) | 2015-09-24 | — | — | WO | disclosed |
| EP-2918589-A1 | ADENINE DERIVATIVE AS PI3K INHIBITOR | Intellikine, LLC (US) | 2015-09-16 | — | — | EP | disclosed |
| US-20140328796-A1 | 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS, INC. | 2014-11-06 | — | — | US | disclosed |
| US-8785378-B2 | Macrocyclic peptides as inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| EP-1863833-B1 | PROCESS FOR PREPARING MACROCYCLIC COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2013-09-18 | — | — | EP | disclosed |
| US-8445430-B2 | Cyclic carboxamide compounds and analogues thereof as of hepatitis C virus | ACHILLION PHARMACEUTICALS, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-RE40525-E1 | Hepatitis C inhibitor tri-peptides | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2008-09-30 | — | — | US | disclosed |
| US-RE40525-E1 | Hepatitis C inhibitor tri-peptides | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2008-09-30 | — | — | US | disclosed |
| US-7384952-B2 | Pyrazolopyrimidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-06-10 | — | — | US | disclosed |
| WO-2008019477-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-21 | — | — | WO | disclosed |
| US-20070281937-A1 | Ion Channel Modulators | SCION PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| EP-1857459-A2 | Pyrazolopyrimidine compound and a process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 2007-11-21 | — | — | EP | disclosed |
| US-20070203194-A1 | Calcium channel modulators comprising 3-thio-4H-1,2,4-triazoles or S-oxides thereof; angina, hypertension, congestive heart failure, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders | SCION PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | US | disclosed |
| US-20070203194-A1 | Calcium channel modulators comprising 3-thio-4H-1,2,4-triazoles or S-oxides thereof; angina, hypertension, congestive heart failure, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders | SCION PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | US | disclosed |
| WO-2004093915-A1 | PHARMACEUTICAL COMPOSITIONS FOR HEPATITIS C VIRAL PROTEASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL, GMBH (DE) | 2004-11-04 | — | — | WO | disclosed |
| WO-2003066103-A1 | PHARMACEUTICAL COMPOSITIONS FOR HEPATITIS C VIRAL PROTEASE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-08-14 | — | — | WO | disclosed |